# GNTech

GNTech is an other based in Seongnam, South Korea.

## Overview

- **Organization type:** other
- **Headquarters:** Seongnam, South Korea
- **Region:** Asia
- **Address:** Seongnam, South Korea
- **Assets under management:** Undisclosed
- **Website:** gntech.med.br

## Regulatory record

- **Reports private funds:** No

## About

GnTech is a company based in Florianopolis, Brazil. It specializes in pharmacogenetics, focusing on the health technology sector. GnTech offers pharmacogenetic testing services that analyze an individual's genetic profile to optimize medication efficacy and assess the risk of side effects.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- Plymouth, UK

## People

- Dr. Guido Boabaid May — CEO, Founder, Psychiatrist

## Questions

### How does GNTech source its commercial opportunities?

The firm primarily goes direct to patient via its e-commerce website, where individuals can purchase at-home buccal swab kits without a prescription. It also builds physician-channel volume through its network of more than 5,000 partner doctors who review and interpret the digital reports in clinical settings. Media coverage in Brazilian outlets functions as a third acquisition funnel by amplifying patient success stories.

### Which therapeutic areas does GNTech's tests actually cover?

GNTech markets panelized tests across distinct verticals. Its PsicoGene line targets psychiatric conditions — major depressive disorder, generalized anxiety, ADHD, bipolar disorder, and autism spectrum disorder — while the top-tier TotalGene panel adds gene–drug interaction analyses for oncology, cardiology, gastroenterology, and infectious disease agents.

### What is GNTech's known posture on clinical evidence and validation?

The firm cites peer-reviewed research on its website, including the finding from McInnes et al. (2020) that 99.5% of individuals carry at least one actionable pharmacogenetic variant, and it references relative outcome improvements from published pharmacogenomic studies. GNTech does not, however, publish its own independent prospective trial data on its website, relying instead on clinical case numbers and third-party literature to support its marketing claims.

### Does GNTech operate purely direct-to-consumer or also through institutional healthcare channels?

GNTech operates a hybrid model. Consumers can purchase kits directly online without a prescription, but the company also accepts medical requisitions for cases involving health plans or insurers, positioning the test as reimbursable in certain contexts. The interpretive report must be reviewed by a licensed physician regardless of purchase path, making the product functionally a physician-mediated diagnostic in both B2C and B2B workflows.

### How is GNTech capitalized, and does it have outside investors?

No information about GNTech's funding structure, outside investors, or institutional backing is publicly available. The firm does not disclose any venture capital rounds, family office backing, or debt facilities on its website or in accessible media. The entity's capital structure remains entirely opaque based on current sources.

## Related profiles

- [Silver Portal Capital](https://altss.com/profile/silver-portal-capital)
- [Tudor](https://altss.com/profile/tudor)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/gntech

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology